Cilcare is proud to announce its selection as a laureate of the FEDER program (European Regional Development Fund) for its strategic “Cilcare 2030” project, supported by the Région Occitanie.
Through this initiative, Cilcare will accelerate the deployment of next-generation technologies dedicated to hearing research and precision medicine, combining artificial intelligence, translational science, advanced diagnostics, and alternative preclinical models.
The project, supported up to 0,6M€ over a three-year period, represents a major step in Cilcare’s ambition to strengthen its position as a global leader in auditory science while contributing to the development of a highly innovative health ecosystem in Occitanie.
Preclinical innovation platform
FEDER funding will enable Cilcare to accelerate the transfer and integration of its existing breakthrough preclinical innovations into a unified in-house platform for auditory research.
This includes the industrialization of organoid-based models の予防および治療を目的とした革新的な治療法の開発を支援しています。 3D bioprinted inner ear systems, within a GLP-compliant environment, supporting more human-relevant and ethical approaches to drug development.
“These technologies have the potential to transform the way auditory therapeutics are evaluated,” said Sylvie Pucheu, Co-founder and Director of Preclinical Innovation. “They provide more predictive, translational, and ethical research models. This initiative fully contributes to the biotherapies ecosystem in the Région Occitanie. It will support biotech and pharmaceutical companies seeking these capabilities and ultimately benefit patients awaiting new therapeutic options.”
Clinical data generation, AI and biomarker development
The initiative will also strengthen Cilcare’s capabilities in artificial intelligence, data science, and clinical research to advance auditory diagnostics and biomarker discovery.
A key focus will be the continuation of observational clinical studies, building on the DIAMANT and SAPHIR programs, to better characterize auditory profiles, patient variability, and disease comorbidities, generating real-world data for predictive modelling and biomarker discovery.
Funding will also support mobile and advanced hearing assessment tools for earlier and more accessible auditory screening.
“Over the past years, Cilcare has built proprietary analytical tools and advanced data science capabilities that truly differentiate us in the hearing research space,” said Jérôme Geoffroy, CFO and Chief Data Officer. “With FEDER funding, we will accelerate this trajectory — leveraging AI to extract the full value of hearing data, defining novel biomarkers from complex preclinical and clinical datasets, and developing mobile hearing assessment capabilities in partnership with industry players. We are turning cutting-edge data science into a concrete competitive advantage for our clinical programs, our partners, and the hearing field as a whole.”
Through the “Cilcare 2030” project, the company aims to advance predictive, data-driven hearing healthcare and improve therapeutic development through clinical insight and innovation.
